Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share, targeting gross proceeds of approximately $2.1 million.
According to the company, net proceeds will support cash reserves, clinical development of the S-100 molecule at subsidiary Applied Lipid Technologies, and general working capital. The financing is subject to Canadian Securities Exchange approval, and all securities will carry a four‑month hold period under Canadian securities laws.
Lobe Sciences (OTCQB:LOBEF) reported the results of its July 30, 2026 Annual General and Special Meeting, where 152,807,032 common shares (about 49.6% of outstanding shares) were represented and all resolutions were approved. Shareholders elected five directors and re-appointed Davidson & Company as auditor, with support levels around 99.8%.
Investors approved a new Long-Term Incentive Plan that cuts the maximum shares issuable under all security-based compensation from 40% to 20%, and ratified prior RSU grants. A special resolution amending constating documents, including eliminating the preferred share class, passed with 99.773% support, which management says simplifies capital structure and governance.
Management outlined a strategy of advancing pharmaceutical assets via subsidiaries and ongoing work toward a future senior exchange listing. Updates highlighted preclinical and regulatory progress for Cynaptec’s L-130 program for chronic cluster headache and Applied Lipid Therapeutics’ S-100 sickle cell disease program, including CMC work and an FDA Orphan Drug Designation application under review.
Lobe Sciences (OTCQB:LOBEF) filed its Management Information Circular for the Annual General and Special Meeting on July 30, 2026, 11:00 a.m. Vancouver time, in Vancouver with virtual Microsoft Teams access.
Shareholders will vote on directors, auditors, a new LTIP, prior RSU grants, and amendments to constating documents, and receive strategy and pipeline updates including uplisting plans and three subsidiary programs.
Lobe Sciences (OTCQB:LOBEF) settled C$1,372,761.20 of accrued management and director fees by issuing 12,749,643 common shares at C$0.11, increasing insider ownership to over 40%. The Canadian Securities Exchange accepted the issuance.
The company reported C$4.96 million in cash and short-term investments and C$2.12 million in R&D spending in the first half of fiscal 2026, reflecting active clinical development of its L-130 and S-100 programs via majority-owned subsidiaries.
Lobe Sciences (OTCQB:LOBEF) plans to settle C$1,372,761.20 of management and director fee debt by issuing 12,749,643 common shares at $0.11 per share, subject to Canadian Securities Exchange approval. The move preserves cash for operations while the company advances its L-130 and S-100 clinical programs.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will attend the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel in New York to meet institutional investors, pharma companies, and strategic partners.
The company highlighted its two lead programs: L-130 (psilocin mucate), advanced by Cynaptec (Lobe owns 64%), and S-100, which is completing CMC work ahead of a planned Phase 2a study.
Lobe Sciences (OTCQB:LOBEF) reported Q2 2026 interim results and operational progress. Cash was $1,071,199 with short-term investments of $3,889,632 and net working capital of $2,160,073. R&D for the six months was $2,115,338; operating cash used was $2,637,862. Net loss for the quarter was $3,693,896. The company advanced two core programs (L-130 for chronic cluster headache and S-100 for sickle cell disease) and completed a non-brokered private placement raising approximately $950,000.
Lobe Sciences (OTCQB:LOBEF) commented on the White House April 2026 Executive Order endorsing expanded research into neurological and mental health treatments. The company said the action could enable study of compounds by safety and clinical potential rather than historical scheduling. Lobe highlighted its subsidiary Cynaptec and drug candidate L-130, being developed as a non-hallucinogenic candidate for chronic cluster headache and substance use disorder.
Lobe Sciences (OTCQB:LOBEF) engaged Massive Intelligence Pty Ltd for investor relations and corporate communications under a letter dated April 15, 2026.
The initial engagement is for three months from April 15, 2026 for a total cash retainer of US$11,800; an optional six-month renewal would add US$31,500. No securities will be issued in connection with the engagement.
Lobe Sciences (OTCQB:LOBEF) closed a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 20, 2026.
Proceeds will fund working capital, advance the S-100 drug candidate for sickle cell disease, and provide capital to subsidiary Applied Lipid Technologies to support development toward human clinical trials; the company has procured required active pharmaceutical ingredient. Securities are subject to a four-month Canadian hold period and are not registered in the United States.